文献速递创伤骨科骨质疏松与代谢性骨病

司美格鲁肽与替尔泊肽较DPP-4抑制剂降低老年2型糖尿病患者的跌倒和股骨骨折风险

Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.
PubMed 文献 · Osteoporos Int · 2026-07-11

这项回顾性队列研究基于TriNetX数据库(2018-2025),纳入年龄≥65岁、BMI≥25 kg/m²的2型糖尿病成人,比较司美格鲁肽或替尔泊肽与DPP-4抑制剂的1年股骨骨折和跌倒风险。经1:1倾向评分匹配后,司美格鲁肽组27,896例、替尔泊肽组12,808例,两种药物均与股骨骨折和跌倒风险显著降低相关。

要点

  • 司美格鲁肽和替尔泊肽较DPP-4抑制剂显著降低1年股骨骨折风险。
  • 两种药物也显著降低跌倒风险,亚组分析跌倒下降一致。
  • BMI≥30 kg/m²患者中骨折风险下降更明显。

核心结论

  • 在老年2型糖尿病合并超重/肥胖患者中,司美格鲁肽和替尔泊肽较DPP-4抑制剂与股骨骨折和跌倒风险显著降低相关,提示降糖之外的骨骼肌肉获益。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据库(2018-2025),纳入年龄≥65岁、2型糖尿病且BMI≥25 kg/m²的成人。
  • 司美格鲁肽或替尔泊肽使用者与DPP-4抑制剂使用者按1:1倾向评分匹配比较,主要结局为1年股骨骨折,次要结局为跌倒。
  • 匹配后司美格鲁肽/DPP-4比较纳入27,896例,替尔泊肽/DPP-4比较纳入12,808例。

主要发现

  • 司美格鲁肽组股骨骨折发生率为0.3%,DPP-4抑制剂组为0.5%(HR 0.488;95% CI 0.367-0.649;P < 0.0001)。
  • 替尔泊肽组股骨骨折发生率为0.2%,DPP-4抑制剂组为0.4%(HR 0.452;95% CI 0.280-0.729;P = 0.0008)。
  • 司美格鲁肽组跌倒发生率为3.6%,DPP-4抑制剂组为5.4%(HR 0.663;95% CI 0.612-0.718;P < 0.0001)。
  • 替尔泊肽组跌倒发生率为3.6%,DPP-4抑制剂组为5.7%(HR 0.664;95% CI 0.591-0.747;P < 0.0001)。
  • 亚组分析显示跌倒风险降低在各分类中一致,而骨折风险降低在BMI≥30 kg/m²患者中更明显。

临床怎么用

  • 对老年2型糖尿病合并超重/肥胖患者,司美格鲁肽或替尔泊肽可作为兼顾降糖与降低跌倒及股骨骨折风险的优选方案之一。
  • BMI≥30 kg/m²的患者可能从这两种药物中获得更明显的骨折风险下降,临床决策时可优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors. PURPOSE: Incretin-based therapies may influence musculoskeletal health. This study evaluated the association of semaglutide and tirzepatide with femoral fractures and falls in older adults with type 2 diabetes (T2DM) and overweight or obesity. METHODS: This retrospective cohort study using the TriNetX database (2018-2025) included adults aged ≥ 65 with T2DM and BMI ≥ 25 kg/m2. Patients receiving semaglutide or tirzepatide were compared with those on dipeptidyl peptidase-4 (DPP-4) inhibitors using 1:1 propensity score matching. Primary and secondary outcomes were 1-year femoral fracture and falls, respectively. RESULTS: After matching, 27,896 patients were included in the semaglutide/DPP-4 comparison and 12,808 in the tirzepatide/DPP-4 comparison. Femoral fractures were significantly lower with semaglutide (0.3% vs. 0.5%; HR 0.488; 95% CI 0.367-0.649; P < 0.0001) and tirzepatide (0.2% vs. 0.4%; HR 0.452; 95% CI 0.280-0.729; P = 0.0008) compared with DPP-4 inhibitors. Fall risk was also reduced for both semaglutide (3.6% vs. 5.4%; HR 0.663; 95% CI 0.612-0.718; P < 0.0001) and tirzepatide (3.6% vs. 5.7%; HR 0.664; 95% CI 0.591-0.747; P < 0.0001). Subgroup analyses showed consistent fall reduction across categories, while fracture reduction was more pronounced in patients with BMI ≥ 30 kg/m2. CONCLUSION: In older adults with T2DM and overweight/obesity, semaglutide and tirzepatide were associated with significantly lower risks of femoral fracture and falls compared with DPP-4 inhibitors, suggesting musculoskeletal benefits beyond glycemic control.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen HY, Wu JY, Chu YH, et al. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes. Osteoporos Int. 2026. PMID: 42435064. doi:10.1007/s00198-026-08134-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。